Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04280822 | Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma | recruiting | Phase 3 | 400 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05547529 | The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer | recruiting | Phase 3 | 156 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Oct 4, 2022 |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05201430 | Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer(RCNAC) | recruiting | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04787354 | Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) | recruiting | Phase 3 | 976 | Hallym University Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05194878 | Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers | recruiting | Phase 3 | 840 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT05086614 | Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | recruiting | Phase 3 | 2,500 | Fudan UniversityOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04997837 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | recruiting | Phase 3 | 433 | Fudan UniversityOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04483076 | Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer(RESONANCE-II) | recruiting | Phase 3 | 524 | Chinese PLA General HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04288999 | Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer(JCOG1801) | recruiting | Phase 3 | 110 | National Cancer Center Hospital EastOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04135664 | Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 176 | Shanghai Chest HospitalOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03941561 | S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC） | recruiting | Phase 3 | 1,006 | Fudan UniversityOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03961373 | Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer(Neo-D2plus) | recruiting | Phase 3 | 539 | University of SienaOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT03925662 | Mebendazole as Adjuvant Treatment for Colon Cancer | recruiting | Phase 3 | 40 | Sherief Abd-ElsalamOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT03671252 | Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation | recruiting | Phase 3 | 776 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03731442 | Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients | recruiting | Phase 3 | 300 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT03125980 | Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer | recruiting | Phase 3 | 1,370 | Fudan UniversityOTHER | 1 | Apr 24, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Oct 4, 2022source: clinicaltrials